Skip to main content
. 2015 Nov;3(19):284. doi: 10.3978/j.issn.2305-5839.2015.11.14

Table 3. Patient and disease characteristics of each treatment group.

Characteristics Group 1
 Group 2
 P value
Number % Number %
Age
   17-<40 13 17 10 13 0.06
   40-49 41 52 45 55 0.07
   50-60 22 28 23 29 0.10
   61-65 2 3 2 3 0.09
Mean age 46 – 47 – 0.10
Median age 46 – 46 – 0.10
Performance status (ECOG)
   0 50 64 48 60 0.07
   1 21 27 25 31 0.06
   2 7 9 7 9 0.09
Performance status (median) 0 – 0 – 0.10
Pathological classification
   Ductal 59 76 60 75 0.10
   Lobular 19 24 20 25 0.10
   Other 0 – 0 – –
Pathological grade
   1 2 3 2 2.5 0.08
   2 66 84 66 82 0.07
   3 10 13 12 15 0.08
Grade median 2 – 2 – 0.10
Tumor stage
   pT0N1 0 0 0 0 –
   pT2N0 4 5 6 7 0.09
   pT1N1 9 12 5 6 0.05
   pT2N1 23 29 23 28 0.09
   pT3N1 4 5 7 8 0.07
   pT4N0-1 3 4 2 2 0.06
   pT1-3N2 28 36 29 36 0.10
   pT1-3N3 7 9 8 10 0.09
Tumor stage median pT2N2 pT2N2 0.10
Surgery
   Modified radical mastectomy (MRM) 60 77 60 75 0.09
   Breast conservative surgery (BCS) 18 23 20 25 0.08
   Others 0 0 0 0 -
Other risk features
   Lymph node capsular invasion
      Absent 70 89 71 89 0.10
      Present 8 11 9 11 0.10
   Lymphovascular invasion
      Absent 73 93 75 93 0.10
      Present 5 7 5 7 0.10
   Perinural invasion
      Absent 74 95 76 95 0.09
      Present 4 5 4 5 0.10
   Extensive intraducatal component
      Absent 68 87 69 86 0.09
      Present 10 13 11 14 0.10
   Surgical margin: for BCS
      Negative 13 72 15 75 0.08
      Positive 5 28 5 25 0.10
   Post-operative radiotherapy
      Yes 71 91 73 91 0.10
      No 7 9 7 9 0.10